Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy
caused by extracellular deposition of transthyretin, normally involved in the transportation of …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart
failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin …

Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an
underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils …

Background Transthyretin amyloid cardiomyopathy is caused by the deposition of
transthyretin amyloid fibrils in the myocardium. The deposition occurs when wild-type or …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Sharmila Dorbala, MD, MPH, FASNC, Chair*; Yukio Ando, MD, PhD†; Sabahat Bokhari,
MD‡; Angela Dispenzieri, MD § ; Rodney H. Falk, MD*; Victor A. Ferrari, MD∥; Marianna …

Aims Transthyretin cardiac amyloidosis (ATTR-CA) has been reported in patients with aortic
stenosis (AS) but its prevalence and phenotype are not known. We examine elderly patients …

Background—Cardiac transthyretin (ATTR) amyloidosis is a progressive and fatal
cardiomyopathy for which several promising therapies are in development. The diagnosis is …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Tissue deposition of protein fibrils causes a group of rare diseases called systemic
amyloidoses. This Seminar focuses on changes in their epidemiology, the current approach …